Aardvark Therapeutics, Inc. (AARD)

NASDAQ: AARD · Real-Time Price · USD

4.070

-0.830 (-16.94%)

At close: Mar 20, 2026, 4:00 PM EDT

4.390

+0.320 (7.86%)

After-hours: Mar 20, 2026, 6:03 PM EDT

Aardvark Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2023
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Selling, General & Admin	10.77	5.31	2.17	2.7
Research & Development	42.7	17.36	4.48	7.17
Other Operating Expenses	-	0.12	0.76	1.49
Total Operating Expenses	53.47	22.79	7.42	11.36
Operating Income	-53.47	-22.79	-7.42	-11.36
Interest Income	4.73	2.41	1.42	0.12
Other Non-Operating Income (Expense)	-0.03	-0.22	-1.22	-2.32
Total Non-Operating Income (Expense)	4.7	2.2	0.21	-2.2
Pretax Income	-48.77	-20.59	-7.21	-13.56
Net Income	-48.77	-20.59	-7.21	-13.56
Net Income to Common	-48.77	-20.59	-7.21	-13.56
Shares Outstanding (Basic)	15	4	4	4
Shares Outstanding (Diluted)	15	4	4	4
Shares Change (YoY)	273.85%	0.90%	1.78%	-
EPS (Basic)	-4.30	-5.15	-1.82	-3.49
EPS (Diluted)	-4.30	-5.15	-1.82	-3.49
Free Cash Flow	-45.19	-18.2	-5.82	-5.82
Free Cash Flow Per Share	-2.98	-4.55	-1.47	-1.50
EBITDA	-53.44	-22.77	-7.42	-11.36
EBIT	-53.47	-22.79	-7.42	-11.36

Updated Sep 30, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q